The evolving UK scene surrounding entheogens is increasingly complex, demanding careful exploration. While scientific inquiry into compounds like psilocybin and copyright continues to unfold, and patient availability via private clinics is expanding, the policy framework remains uncertain. This presents a challenging situation for both individuals